Marvel Biosciences’ MB204 Shows Promise in Autism Study

Marvel Biosciences Corp (TSE:MRVL) has released an update.

Marvel Biosciences Corp. announced that their drug MB204 showed significant improvement in social behavior in a mouse model of autism after just one dose. The study, conducted in France, demonstrated a clear dose-response relationship, with high doses of MB204 enhancing social interactions beyond levels seen in normal mice. The company is optimistic about MB204’s potential and is preparing to publish the findings.

For further insights into TSE:MRVL stock, check out TipRanks’ Stock Analysis page.